GlaxoSmithKline (NYSE:GSK) has submitted a marketing application in Japan seeking approval for daprodustat for the treatment of patients with renal anemia due to chronic kidney disease.
If approved, the oral hypoxia-inducible factor prolyl hydroxylase inhibitor will be distributed by Kyowa Kirin Co., Ltd. (OTCPK:KYKOF) under a 2018 commercialization agreement.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.